PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells. PATIENTS AND METHODS: We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22 CAR T-cell persistence, and cytokine profiling. RESULTS: Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis-like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation. CONCLUSION: In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.
PURPOSE:Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22chimeric antigen receptor (CAR) T cells. PATIENTS AND METHODS: We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22CAR T-cell persistence, and cytokine profiling. RESULTS: Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis-like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation. CONCLUSION: In the largest experience of CD22CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.
Authors: Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen Journal: Blood Date: 2017-04-13 Impact factor: 22.113
Authors: Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall Journal: Lancet Date: 2014-10-13 Impact factor: 79.321
Authors: Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry Journal: Clin Cancer Res Date: 2019-05-20 Impact factor: 12.531
Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808
Authors: Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Juliane Gust; W Conrad Liles; Mark M Wurfel; José A López; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Cameron J Turtle Journal: Blood Date: 2017-09-18 Impact factor: 22.113
Authors: Donna Przepiorka; Chia-Wen Ko; Albert Deisseroth; Carolyn L Yancey; Reyes Candau-Chacon; Haw-Jyh Chiu; Brenda J Gehrke; Candace Gomez-Broughton; Robert C Kane; Susan Kirshner; Nitin Mehrotra; Tiffany K Ricks; Deborah Schmiel; Pengfei Song; Ping Zhao; Qing Zhou; Ann T Farrell; Richard Pazdur Journal: Clin Cancer Res Date: 2015-09-15 Impact factor: 12.531
Authors: Elad Jacoby; Sang M Nguyen; Thomas J Fountaine; Kathryn Welp; Berkley Gryder; Haiying Qin; Yinmeng Yang; Christopher D Chien; Alix E Seif; Haiyan Lei; Young K Song; Javed Khan; Daniel W Lee; Crystal L Mackall; Rebecca A Gardner; Michael C Jensen; Jack F Shern; Terry J Fry Journal: Nat Commun Date: 2016-07-27 Impact factor: 14.919
Authors: Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall Journal: Nat Med Date: 2017-11-20 Impact factor: 53.440
Authors: Paolo Strati; Sairah Ahmed; Partow Kebriaei; Loretta J Nastoupil; Catherine M Claussen; Grace Watson; Sandra B Horowitz; Anne Rain T Brown; Bryan Do; Maria A Rodriguez; Ranjit Nair; Elizabeth J Shpall; Michael R Green; Sattva S Neelapu; Jason R Westin Journal: Blood Adv Date: 2020-07-14
Authors: Kazusa Ishii; Marie Pouzolles; Christopher D Chien; Rebecca A Erwin-Cohen; M Eric Kohler; Haiying Qin; Haiyan Lei; Skyler Kuhn; Amanda K Ombrello; Alina Dulau-Florea; Michael A Eckhaus; Haneen Shalabi; Bonnie Yates; Daniel A Lichtenstein; Valérie S Zimmermann; Taisuke Kondo; Jack F Shern; Howard A Young; Naomi Taylor; Nirali N Shah; Terry J Fry Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Michael C Jensen; Julie R Park; Nicholas A Vitanza; Adam J Johnson; Ashley L Wilson; Christopher Brown; Jason K Yokoyama; Annette Künkele; Cindy A Chang; Stephanie Rawlings-Rhea; Wenjun Huang; Kristy Seidel; Catherine M Albert; Navin Pinto; Juliane Gust; Laura S Finn; Jeffrey G Ojemann; Jason Wright; Rimas J Orentas; Michael Baldwin; Rebecca A Gardner Journal: Nat Med Date: 2021-07-12 Impact factor: 53.440
Authors: Dimitrios L Wagner; Enrico Fritsche; Michael A Pulsipher; Nabil Ahmed; Mohamad Hamieh; Meenakshi Hegde; Marco Ruella; Barbara Savoldo; Nirali N Shah; Cameron J Turtle; Alan S Wayne; Mohamed Abou-El-Enein Journal: Nat Rev Clin Oncol Date: 2021-02-25 Impact factor: 66.675
Authors: Cristina Gutierrez; Anne Rain T Brown; Heather P May; Amer Beitinjaneh; R Scott Stephens; Prabalini Rajendram; Joseph L Nates; Stephen M Pastores; Ananda Dharshan; Alice Gallo de Moraes; Matthew K Hensley; Lei Feng; Jennifer N Brudno; Janhavi Athale; Monalisa Ghosh; James N Kochenderfer; Alejandro S Arias; Yi Lin; Colleen McEvoy; Elena Mead; Jason Westin; Natalie Kostelecky; Agrima Mian; Megan M Herr Journal: Crit Care Med Date: 2022-01-01 Impact factor: 7.598